{"entity":{"id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","aka":[],"tldr":"A liver cancer oncologist who has been on the steering group of several global HCC trials with strong Asian enrolment.","summary":"Ho Yeong Lim is Professor of Medical Oncology at Samsung Medical Center in Seoul, specialising in hepatocellular carcinoma. He has served on the steering groups of several global liver cancer trials with strong Asian enrolment, including IMbrave150, which tested atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. His publications include the IMbrave150 report, and he has contributed to immunotherapy combination trials and Asian subgroup analyses of first-line regimens. His interests are systemic therapy and clinical trials in liver cancer.","asOf":"2026-09-08","links":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lim%20HY%5BAuthor%5D%20hepatocellular%20carcinoma%20Samsung"}],"tags":[],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["atezolizumab"],"companies":[],"institutions":["samsung-medical-center"],"pathways":[],"terms":[],"trials":["imbrave150"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; hepatocellular carcinoma","institutionId":"samsung-medical-center","specialisms":["Hepatocellular carcinoma","Systemic therapy","Clinical trials"],"profiles":[{"label":"Samsung Medical Center","url":"https://www.samsunghospital.com/gb/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lim%20HY%5BAuthor%5D%20hepatocellular%20carcinoma%20Samsung"}],"papers":[{"title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1915745"}]},"route":"/people/lim-ho-yeong/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"}],"institution":[{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/"}],"trial":[{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/"}],"paper":[{"id":"paper-imbrave150-nejm-2020","kind":"paper","name":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","route":"/key-papers/paper-imbrave150-nejm-2020/"}]}}